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ABSTRACT
Background: The incidence of cervical cancer is up to
sixfold higher among First Nation women in Canada than in
the general population. This is probably due to lower
participationratesincervicalcancerpreventionprogrammes.
Objective: To raise screening participation in this
underserved population by launching an alternative
approach to (Pap)anicolaou testing in
a clinicdnamely, vaginal self-sampling followed by
human papillomavirus (HPV) diagnostics.
Methods: Good relationships were established with
a First Nation community of the Northern Superior
region in Northwest Ontario, and then 49 community
women, aged 25e59, were recruited, who provided
a vaginal self-sample and answered a questionnaire.
Frequency distributions and cross-tabulations were
used to summarise the data. Associations between
categorical variables were assessed using the c
2 test
of association, or the GoodmaneKruskal g if both
variables had ordered categories. Self-collected
samples were tested for integrity and HPV using
optimised molecular biological methods.
Results: The majority of participants (87.2%) were
amenable to future HPV screening by self-sampling.
This ﬁnding was independent of age, educational level
and a previous history of abnormal Pap tests.
Interestingly, the preferred way to learn about sexual
health remained through interaction with healthcare
professionals. As deﬁned by the presence of
a housekeeping gene, self-sample integrity was high
(96%). Using polymerase chain reaction-based
Luminex typing, the overall HPV positivity was 28.6%
(ie, with either a low- or high-risk type) and 16.3%
were infected with a high-risk type such as HPV16.
Conclusion: InthispilotstudyofFirstNationwomen,self-
samplingandHPVtestingwaswellreceivedandself-sample
quality was excellent. A larger survey to be conducted in
other Northern Superior communities in Northwest Ontario
will determine whether this approach could become a viable
screening strategy for First Nation women.
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ARTICLE SUMMARY
Article focus
- Independent international studies have shown
that self-sampling for cervical screening is safe
and equally reliable as sampling by a health
professional.
- Self-sampling has been reported to increase
screening compliance for women who have
never or not regularly been screened.
- To date, self-sampling has not been studied in
First Nation (aboriginal) women in Canada, an
underserved population in whom cervical cancer
is up to six times higher than in the general
population.
Key messages
- First Nation women participating in this pilot
study were amenable to self-collection and
87.2% reported that this alternative screening
approach would probably increase their
screening participation.
- The preferred way to learn about sexual health is
through healthcare professionals.
- Self-sample integrity was high (96%) as deﬁned
by the presence of a housekeeping gene. Using
polymerase chain reaction-based Luminex
typing, 28.6% of the participating women were
HPV-positive (ie, with either a low- or high-risk
type) and 16.3% were infected with a high-risk
type such as HPV16.
Strengths and limitations of this study
- Good relations with the largest First Nation
community in Northwest Ontario have been
established and our pilot study forms a basis
for promoting cervical cancer screening in other
First Nation communities in that region.
- A larger study is needed to validate our ﬁndings
and to achieve good statistical power.
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Open Access ResearchINTRODUCTION
Cervical cancer is among the top three cancers affecting
women world wide
1 and the third most common cancer
in Canada among women aged 20e49.
2 Aboriginal
populations appear to be particularly affected by this
disease. In Canada, cervical cancer is up to sixfold higher
in First Nation women than in the general population in
the Northwest Territories,
3 Manitoba
4 and Ontario.
5
Similarly, aboriginal women from Australia and the USA
have a higher cervical cancer prevalence than the
general population in those countries.
67
Most women who develop cervical cancer have been
infrequently or never screened,
8 yet such screening is
crucial for early detection of precancerous lesions.
Accessing health information and preventive medical
services can be challenging for First Nation women
91 0 d
their communities are generally rural and remote,
transportation is a limiting factor and culturally appro-
priate, on-site health and educational services may be
inadequate. These challenges (as well as the lack of an
electronic database to identify seldom or never screened
Ontario women) probably contribute to irregular
participation of First Nation women in cervical screening
in comparison with other Canadian women.
41 11 2
Lack of accessible or appropriate screening facilities
could be overcome by offering a screening test based on
self-collection. Indeed, the Canadian National Aborig-
inal Health Organization suggested that HPV testing
based on self-sampling may be a good alternative to
(Pap)anicolaou testing to increase participation among
First Nation women.
13 In addition, a comprehensive
review by the International Agency for Research on
Cancer Working Group concluded that human papillo-
mavirus (HPV) testing is a justiﬁable strategy for cervical
cancer prevention.
14 Self-collection of vaginal samples
for HPV testing has been investigated as a potential
cervical screening method in several populations, with
good uptake (reviewed by Stewart et al
15 and by Huynh et
al
16and references therein
17e20). Two Swedish studies
found that, among women who had not been screened
for more than 6 years, 32e58% participated in self-
sampling.
18 19 Similar ﬁndings have been obtained in
a recent Canadian study, suggesting that Caucasian
women who do not participate in cervical cancer
screening programmes may be willing to provide a self-
collected specimen instead.
17 Furthermore, self-collec-
tion has been observed to be as reliable as sampling
carried out by a doctor for the detection of high-risk
HPV associated with an increased risk of cervical
cancer.
21
A study on cervical cancer screening uptake based on
self-sampling and HPV testing among First Nation
women has never been conducted in Ontario. Before
beginning a large investigation in 10 Northern Superior
communities in Northwest Ontario (box 1), we
conducted a pilot study with 49 First Nation women in
the largest of these communities. Our approach was
based on convenient self-sampling and sensitive HPV
testing, rather than (Pap)anicolaou screening. To assess
the feasibility of this alternative method we used a ques-
tionnaire in which demographics and cervical cancer
knowledge, self-sampling and sexual health were inves-
tigated. Sample adequacy and HPV testing methods were
also evaluated.
METHODS
Participating First Nation community
Fort William First Nation (FWFN), the community that
participated in our pilot study, is situated near Thunder
Bay on the northern shore of Lake Superior in North-
west Ontario, Canada. FWFN was created in 1853, as
a result of the 1850 Robinson-Superior Treaty. With
a total of 1798 individuals registered, of whom 832 live
on-reserve, FWFN is the largest of the Northern Superior
communities (box 1). The mean population of all
communities is 313 (range 70e832). We chose these
communities for our investigation since they are part of
one strategic region of the Anishinabek Nation inhab-
iting the northern shore of Lake Superior from Pigeon
River to Batchawana Bay. They are under the healthcare
portfolio held by the Regional Grand Chief in FWFN.
Approvals
After a meeting with the band council a research
agreement, identifying potential beneﬁts for the partic-
ipants’ community, data ownership and plans for
dissemination and publication of the results, was signed
in September 2009 by FWFN Grand Chief Peter Collins.
The agreement adhered to guidelines formulated by the
First Nations Information Governance Committee
through ownership, control, access and possession.
22
The study was also approved by the local research ethics
board of Thunder Bay Regional Health Sciences Centre
(TBRHSC REB#2009125). The on-site Dilico family
health team (DFHT) agreed to recruit participants and
provide feedback about the study approach.
Participant recruitment
A DFHT nurse practitioner (project nurse) served as
primary contact for the participating women. To enrol
approximately 50 volunteers, recruitment and
Box 1 Participating Northern Superior communities in
alphabetical order
- Fort William First Nation
- Gull Bay First Nation
- Lake Nipigon First Nation
- Long Lake No 58 First Nation
- Pays Plat First Nation
- Pic River First Nation
- Pic Mobert First Nation
- Red Rock First Nation (Lake Helen)
- Rocky Bay First Nation
- Whitesand First Nation
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November and 18 December, 2009 through a commu-
nity meeting with an information poster; ﬂyers posted in
public places within the community; ﬂyers sent to all
community households through the weekly Band news-
letter and ﬂyers distributed at parenting workshop
nights through the Band ofﬁce and DFHT staff. Women
were not approached individually. All participants auto-
matically took part in incentive draws for ﬁve, CAD$100
grocery certiﬁcates.
Participant eligibility
Eligibility for our pilot study required that participants:
were female; self-reported First Nation ethnicity; regis-
tered in FWFN; were aged 25e59 years and had
a command of the English language. For safety reasons,
women who knew they were pregnant or menstruating
were excluded. Women were enrolled from age 25 rather
than age 30 because Canadian First Nation women
exhibit earlier onset of cervical cancer than the general
population
4 and HPV testing is recommended at an
earlier age.
23
Protocol
Eligible women who wanted to participate in the pilot
study contacted DFHT staff. The research nurse
provided information orally and through the informed
consent form, which was explained to, and signed by, the
volunteer before taking a self-sample. After taking the
self sample, the questionnaire was answered, numbered
and sent to the research team in a sealed envelope.
Participants could choose whether or not they wanted
their test results sent to their healthcare provider (HCP)
or to their homes, or to both.
Self-sampling
The project nurse provided each participant with
a sterile, plain polyester Dacron swab
15 and trans-
portation tube (Copan Diagnostics Sterile Plain Swab;
licensed in Canada by Inverness Medical: #552C). Swabs
were sent at ambient temperature in the transportation
tube to the National Microbiology Laboratory in
Winnipeg. For conﬁdentiality, HPV test results were
blinded to the project nurse (sent in individually sealed
envelopes, each identiﬁable by the participant’s
number). This ensured that members of the research
team did not have access to the names of the partici-
pants, and the project nurse, to individual test results.
Self-sampled DNA testing
DNA from self-samples was puriﬁed using Roche
MagnaPure (automated, magnetic bead-based DNA
extraction; Roche, Mississauga, Canada), validated
speciﬁcally for HPV genotyping. Sample integrity was
assayed by amplifying the housekeeping gene b-globin by
PCR, as described previously.
24
HPV testing was done by Hybrid Capture II (HCII),
basedonanantibodycapturingRNA:DNAhybrids.
24HCII
generically detects the 13 most common high-risk HPV
types(16,18,31,33,35,39,45,51,52,56,58,59and68)at
a viral load that best correlates with cervical dysplasia. For
speciﬁctyping,ourin-houseLuminextechnology,
25based
onnestedPCRampliﬁcation,
26wasconcomitantlyusedon
all 49 participant samples The Luminex method is less
expensivethancomparablecommercialtestsandhasbeen
successfully used previously.
27
Reporting of results
Only samples that were positive for high-risk HPV were
reported to the participants as “Your sample is positive
with a high-risk HPV” followed by the corresponding
HPV type with which they were infected. Cases testing
negative for high-risk, but positive for low-risk HPV, were
reported to the participants as “Your sample is negative
for high-risk HPV”. When communicating HPV test
results to the participating women, it was emphasised
that this study was not a substitute for their biennial Pap
test. Women who tested positive for a high-risk HPV type
were requested to contact their family doctor or the local
colposcopy clinic at the Thunder Bay Regional Health
Sciences Centre. The research team provided names and
contact information of the principal investigator (IZ)
and the colposcopist (NE).
Statistical analyses
All analyses were carried out using PASW (formerly
SPSS), version 18.0. Data obtained from the question-
naires were examined by frequency distributions and
cross-tabulations. Associations between primary ques-
tions (general, self-sampling and sexual health) and
secondary questions (age, education and abnormal Pap
history) were assessed with the GoodmaneKruskal g
(when both variables were ordinal) or Pearson’s c
2 test
(p#0.05 was considered signiﬁcant). For 232 tables with
any expected counts <5, we used the ‘N 1’ c
2 test.
28
RESULTS
The questionnaire (Appendix) was divided into three
sections: general questions (including participants’
demographicsdtable 1), questions about self-sampling
and questions about sexual healthdthat is, HPV and
cervical cancer (table 2).
General questions
All participants reported having had previous Pap tests,
with 67.3% (33/49) screened at least biennially. Fifty-one
per cent (25/49) of participants reported a previous
abnormal Pap test; this statistic is almost 10-fold higher
than that generally seen in Ontario women.
2 Participants
with previous abnormal Pap tests reported that they had
undergone (52%, 13/25) or were undergoing (36%, 9/
25) treatment. Participants without regular Pap tests
(32.7%, 16/49) reported a hiatus of up to 20 years.
Regular participation in Pap screening was associated
with a higher level of education (p¼0.035) but not with
age or previous history of abnormal Pap tests. Willingness
to self-sample was not associated with previous level of
participation in cervical screening. Four participants were
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(Gardasil); everyone else reported that they had not.
Self-sampling questions
As shown in the Appendix, questions 11 and 12 each had
nine ordinal response options, ranging from 1¼easy/
comfortable to 9¼difﬁcult/uncomfortable. For analysis,
both questions were recorded such that 1e3 became
‘easy/comfortable’, 4e6 ‘mid-range’ and 7e9 ‘difﬁcult/
uncomfortable’. For acceptability of self-sampling,
77.1% (37/48) found self-sampling easy, 6.3% (3/48)
were mid-range, 16.7% (8/48) found it difﬁcult and one
did not answer (question 11). Likewise, 61.7% (29/47)
participants experienced comfort with self-sampling,
23.4% (11/47) were mid-range, 14.9% (7/47) were
uncomfortable and two did not answer (question 12).
Thus the majority of participants found self-sampling
easy and were comfortable with using it. Consequently,
87.2% (41/47) indicated willingness to participate in
self-sampling screening in the future; 8.5% (4/47) did
not know if they would participate more regularly; 4.2%
(2/47) answered no; and two did not answer (question
13). Sixty-seven per cent (32/48) preferred self-sampling
rather than an HCP taking the sample; 18.8% (9/48)
had no preference, while 14.6% (7/48) preferred an
HCP to take their sample (question 14). For cross-tabu-
lations of questions 11e14 with age, educational level or
a previous history of abnormal Pap tests, no statistical
signiﬁcance was achieved in any case.
Sexual health questions
Educational methods
We received 133 suggestions from the 49 participants
about the best way to provide education about sexual
health (question 15). The preferred way to learn about
sexual health was through interaction with an HCP: 35%
(47/133). This was followed by the use of audiovisual
materialdthat is, watching a DVD or looking at a poster:
31.6% (42/133). Learning “on my own” and “together
with my partner” were the least attractive options: 9.8%
(13/133) and 7.5% (10/133), respectively.
Cervical cancer and HPV: knowledge, attitude and behaviour
Participants’ knowledge about cervical cancer and HPV
was scored as follows, with each of two questions having
ﬁve possible correct answers (questions 16 and 17; 19
and 20): 1/5 correct¼some knowledge; 2/5 correct¼fair
knowledge; 3/5 correct¼good knowledge and 4 or 5
correct¼very good knowledge. Importantly, 87.8% (43/
49) had knowledge ranging from “some to very good”
and about half of the participants had “good or very
good” knowledge about cervical cancer. For HPV
biology, 69.4% (34/49) of participants had knowledge
ranging from “some to very good” and about half of the
participants had “good or very good” knowledge.
Awareness about cervical cancer and HPV biology was
not signiﬁcantly associated with age, educational level or a
history of abnormal Pap tests. Most participants (83.7%;
41/49) were not aware that both men and women can
contract HPV infection. Information about cervical
cancer and HPV was mainly obtained from an
Table 1 Demographics of pilot study participants
(n¼49, unless otherwise indicated)
Metric Number Percentage
Ethnicity
First Nation 47 96.0
Metis 2 4.0
Age range*
25e39 27 56.2
40e49 12 25.0
50e59 9 18.8
Educationy
University undergraduate 23 48.9
College 12 25.5
High school or lower 12 25.5
Smoker
At some point 45 91.8
Tampon user 45 91.8
*Only 48 participants responded to the age question.
yOnly 47 participants responded to the education question.
Table 2 Self-sampling and sexual health questions of pilot study participants
Self-sampling Sexual health
87.2% willing to participate in self-sampling
in the future
Educational methods:
35% prefer learning through HCP
31.6% want to use audiovisual material
9.8% want to learn on their own
67% prefer self-sampling to HCP sampling 7.5% want to learn with their partner
77.1% found self-sampling easy and 61.7%
found it comfortable
Knowledge, attitude and behaviour:
87.8% have some to very good knowledge about cervical cancer
69.4% have some to very good knowledge about HPV
83.7% did not know that both men and women can be HPV-infected
Relevance and comprehension of questions:
74% found questions important
69% found questions easy
HCP, healthcare provider.
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Self-sampling and HPV testing in First Nation womenHCPd65.9% (29/44) and ﬁve participants did not
answer the question or know about cervical cancer and
HPV.
Relevance and comprehension of questions
As shown in the Appendix, questions 22 and 23 had nine
ordinal response options ranging from 1¼important/
easy to 9¼not important/difﬁcult. For analysis, these
questions were recorded such that 1e3 became ‘impor-
tant/easy’, 4e6 ‘mid-range’ and 7e9 ‘not important/
difﬁcult’. Seventy-three per cent of participants (36/49)
found the questions important, 6.1% (3/49) were mid-
range and 20.4% (10/49) found them unimportant.
Sixty-nine per cent (34/49) found the questions easy,
14.3 (7/49) were mid-range and 16.3% (8/49) found
them difﬁcult. Thus the majority of participants found
the questions that they were asked to answer in the
questionnaire both easy and important. The importance
of the questions and ease of answering them were posi-
tively related (p<0.001). Comfort was also related to ease
of answering and importance: those who felt most
comfortable with self-sampling perceived the questions
to be easier (p¼0.000) and more important (p¼0.001).
However, no statistical signiﬁcance was reached when
both questions were cross-tabulated with age, education
or abnormal Pap test history.
HPV testing and typing
Integrity of the self-sampled DNA was high, with 47/49
(96%) testing positive for the b-globin housekeeping
gene. Overall, HPV prevalence was 28.6% (14/49); this is
within the 10e30% range found in the Canadian adult
population (Society of Obstetricians and Gynecologists,
Ottawa, Canada).
HPV typing indicated the prevalence of all HPV types
(oncogenic and non-oncogenic) in our participants. The
detected high-risk HPVs (n¼8) included types 16, 35, 52
and 58, which all belong to the phylogenetically related
species A9 (HPV 16, 31, 33, 34, 35, 52 and 58).
29 Inter-
estingly, only one case was positive for HPV 39,
a member of the other high-risk species, A7 (HPV 18, 26,
30, 39, 45, 51, 53, 56 and 59).
29 Several women (n¼6)
were positive for low-risk types 13, 54, 83, 89 and 90,
which belong to the species A9
29 or to other low-risk
groups.
30 Of eight positive cases with high-risk HPV
examined using Luminex, only four cases were positive
using the less sensitive HCII method. No association was
found between testing positive for high-risk HPV and
a previous history of abnormal Pap tests.
DISCUSSION
This initiated investigation examines HPV testing based
on self-sampling in First Nation women in Ontario for
the ﬁrst time. Our pilot study relied on HPV-speciﬁc
DNA assays of vaginal swabs provided by participants to
a blinded nurse volunteer, complemented with partici-
pant feedback via a detailed questionnaire (Appendix).
The participants in this pilot study were positively
inclined towards self-sampling, preferring self-sampling
over HCP sampling. If it becomes clear that self-sampling
is an acceptable screening strategy for First Nation
women in other Northwest Ontario communities,
offering self sampling might be a signiﬁcant alternative
for the recruitment of First Nation women for cervical
cancer screening. Some women (14.7%) reported
discomfort with self-sampling in our pilot study, yet
surprisingly there was no association between discomfort
and preference for HCP sampling.
The majority of our study participants had at least
some knowledge of cervical cancer and HPV. This acute
awareness could be attributable to the patient demo-
graphics in our small sample size: they reported higher
formal educational levels than those of average First
Nation women
31 and several participating women were
local health centre employees. An unexpected ﬁnding
was the low awareness that HPV can infect both men and
women.
Although self-sampling was widely embraced, our
participants still preferred receiving information about
sexual health from an HCP and/or using audiovisual
material; self-study and learning with a partner were
much less popular. Indeed, most participants obtained
HPV knowledge through an HCP, conﬁrming the
important role of this professional group in First
Nations’ health education.
A reliable cervical cancer screening programme has to
use state of the art technology. Our study used the most
common, ‘best practice’ self-sampling device described
in several Canadian studiesdthe Dacron swab.
15 The use
of vaginal tampons
32 is not recommended because DNA
extraction from tampons is time consuming and inefﬁ-
cient (Dr Alberto Severini, unpublished results). Two
available tools can be used for cervical screening: the
Pap test,
33 with its high speciﬁcity but low sensitivity
(detecting only 50% of high-grade cervical lesions), and
the highly sensitive (close to 100%) HPV tests.
11 34 35 As
a primary screening tool, HPV testing can lead to
increased detection of high-grade cervical lesions and
allow larger screening intervals than the Pap test,
33e37
probably resulting in lower costs and higher screening
participation. Furthermore, HPV testing can be conve-
niently performed on self-collected samples, which
further reduces HCP hours and costs. Consequently, our
approach included HPV testing and typing.
Self-sample integrity in our study was found to be
excellent and at least similar to, or even better than, that
found in other studies.
23 The overall HPV prevalence of
28.6%(and16.3%forhigh-risktypes)waswithintheupper
range of the overall Canadian population.
2 Interestingly,
typing revealed almost exclusively HPV types phylogenet-
ically like type 16, but not type 18. Similar ﬁndings were
reported recently in a study involving aboriginal women
from a Northern Plain American Indian reservation
outpatient clinic.
38 Of note, our more sensitive in-house
Luminex technique detected twice as many positive cases
of high-risk HPVas did HCII because HCII was developed
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Luminex technique detects latent HPV infections.
Limitations
Despite the small sample size of our pilot study, similar
studies among Caucasian populations in Canada and
elsewhere are in agreement with our ﬁndings.
15e20 Our
study population differs from that which might be
expected in First Nation communities, which renders
generalisation difﬁcult. The high participation in
regular Pap screening may be connected to a higher
level of education in our participants than among most
Canadian First Nation women. Indeed, we found a posi-
tive, statistically signiﬁcant association between higher
education and participation in cancer screening. On the
other hand, participants who did not have regular Pap
screening reported intervals of up to 20 years. Self-
reported rates have to be considered cautiously because
of over-reporting. Indeed discrepancies between self-
reporting and medical charts have been published by
several independent studies
39 with concordance rates
between 65% and 89%. Our participants also had easy
access to the collaborating health centre in FWFN, which
advocates Pap tests for First Nation women and may
explain the rather high reported rate of previous Pap
tests. The situation differs for members of the other
Northern Superior communities who are required to
travel to larger cities like Thunder Bay for their health
needs (Lee Sieswerda, epidemiologist, Public Health
Unit Thunder Bay, personal communication).
CONCLUSIONS AND FUTURE DIRECTIONS
Our ﬁndings indicate that HPV testing based on self-
sampling is feasible among First Nation women in
Ontario. The majority of women agreed that self-
sampling would be the preferred way of taking the
sample. We are aware, however, that the women who
took part in this pilot study reported having had cytology
at least once and that accessing unscreened First Nation
women is challenging, a factor that will be dealt with in
our larger study. A high sample quality and HPV preva-
lence, comparable to that of the general Canadian
population, was obtained in this pilot study. Based on the
success of this pilot study, we will conduct a larger-scale
study of cervical cancer screening in 10 Northern
Superior communities in Northwest Ontario. In view of
the demographics in the communities we will be able to
recruit more than 800 women. Owing to over-rated self-
reporting when assessing the screening history,
39 a chart
review of previous Pap screening will be performed. A
key question to be answered in the larger study will be
how best to reach and provide sexual health education
to underscreened women. We will also ask participating
women to explicitly rate their discomfort by comparing
HCP sampling with self-sampling.
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